Future potential indications for pharmacotherapy using renin-angiotensin- aldosterone system inhibitory agents

Advances in Clinical and Experimental Medicine

Volumn 19, Issue 3, 2010, Pages 389-398

  Dobrek, Łukasz ^a   Thor, Piotr J ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

ACEI and or ARB novel pharmacotherapy; Angiotensin receptor blocker (ARB); Angiotensin converting enzyme inhibitor (ACEI); Rennin angiotensin aldosterone system (RAAS)

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; EPLERENONE; FOSINOPRIL; GLYCERYL TRINITRATE; ISOSORBIDE; LISINOPRIL; METOCLOPRAMIDE; OMAPATRILAT; PERINDOPRIL; PRAZOSIN; RITANSERIN; SPIRONOLACTONE; VERAPAMIL;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CANCER THERAPY; DRUG EFFECT; GASTROENTEROLOGY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; NEUROLOGY; NONHUMAN; PORTAL HYPERTENSION; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE;

EID: 77954940179     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Zaman MA, Oparil S, Calhoun DA: Drugs targeting the renin-angiotensin- aldosterone system. Nat Rev Drug Discov 2002, 1, 621-636.
2. Brewster UC, Parazella MA: The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004, 116, 263-272.
3. Perazella MA, Setaro JF: Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Cardiol 2003, 10, 184-196.
4. Stanton A: Review: Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2003, 4, 6-10.
5. Fabiani ME, Johnston CI: Spectrum of use for the angiotensin-receptor blocking drugs. Curr Hyperten Rep 1999, 1, 394-401.
6. Unger T, Li J: The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Syst 2004, 5 (Suppl. 1), S7-S10.
7. Swedberg K: Conclusions on the management of heart failure. J Renin Angiotensin Syst 2004, 5, Supp. 1, S34-S36.
8. Metra M, Nodari S, Dei Cas L: Current guidelines in the pharmacological management of chronic heart failure. J Renin Angiotensin Syst 2004, 5 (Suppl. 1), S11-S16.
9. Struthers AD: Aldosterone blockade in heart failure. Journal Renin Angiotensin Syst 2004, 5, Suppl. 1, S23-S27.
10. McMurray J: Angiotensin inhibition in heart failure. J Renin Angiotensin Syst 2004, 5, Suppl. 1, S17-S22.
11. O'Keefe JH, Lurk JT, Kahatapitiya RC, Haskin JA: The renin-angiotensin- aldosterone system as a target in coronary disease. Curr Atheroscler Rep 2003, 5, 124-130.
12. Lefebvre HP, Toutain PL: Angiotensin converting enzyme inhibitors in the therapy of renal diseases. J Vet Pharmacol Therap 2004, 27, 265-281.
13. Karalliedde J, Viberti G: Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006, 20, 239-253.
14. Cooper ME: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004, 17, 16S-20S.
15. Hanes D, Nahar A, Weir MR: The tissue renin-angiotensin-aldosterone system in diabetes mellitus. Curr Hypertens Rep 2004, 6, 98-105.
16. Giacchetti G, Sechi LA, Rilli S, Carey RM: The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005, 16, 120-126.
17. Halkin A, Keren G: Potential indications for angiotensin converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 2002, 112, 126-134.
18. Higgins JP: Can angiotensin converting enzyme inhibitors reverse atherosclerosis? South Med J 2003, 96, 569-579.
19. Duprez DA: Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical study. J Hypertens 2006, 24, 983-991.
20. Finkielstein D, Schweitzer P: Role of angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation. Am J Cardiol 2004, 93, 734-736.
21. Wachtell K, Devereux RB, Lyle PA: Use of beta blockers, angiotensin converting enzyme inhibitors and angiotensin receptor blockers to prevent atrial fibrillation. Curr Cardiol Rep 2006, 8, 356-364.
22. Murray K, Mace LC, Yang Z: Nonantiarrhythmic drug therapy for atrial fibrillation. Heart Rhythm 2007, 4, S88-S90.
23. Freestone B, Beevers DG: The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target? J Hum Hypertens 2004, 18, 461-465.
24. Savelieva I, Camm J: Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? Am Heart J 2007, 154, 403-406.
25. Healey JS, Morillo CA, Connolly SJ: Role of the renin-angiotensin- aldosterone system in atrial fibrillation and cardiac remodeling. Curr Opin Cardiol 2004, 20, 31-37.
26. Dorian P: The future of atrial fibrillation therapy. J Cardiovasc Electrophysiol 2006, 17, Suppl. 2, S11-S16.
27. Madrid AH, Marin I, Cervantes CE, Morell EB, Estevez JE, Moreno G, Parajon JR, Peng J, Limon L, Nannini S, Moro C: Prevention of recurrence in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. Journal Renin Angiotensin Syst 2004, 5, 114-120.
28. Culman J, Baulmann J, Blume A, Unger T: The renin-angiotensin system in the brain: an update. J Renin Angiotensin Syst 2001, 2, 96-102.
29. Llorens-Cortes C, Mendelsohn FAO: Organisation and functional role of the brain angiotensin system. J Renin Angiotensin Syst 2002, 3, Suppl. 1, S39-S48.
30. Hajjar IM, Keown M, Lewis P, Almor A: Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer's disease: an observation study. Am J Alzheimers Dis Other Demen 2008, 23, 77-83.
31. Kehoe PG: Review: The renin-angiotensin-aldosterone system and Alzheimer's disease? J Renin Angiotensin Syst 2003, 4, 80-93.
32. Sokol SI, Portnay EL, Curtis JP, Nelson MA, Hebert PR, Sctaro JF, Foody JM: Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 2004, 63, 208-213.
33. Pelegrini-Da-Silva A, Martins AR, Prado WA: A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception. Neuroscience 2005, 132, 453-463.
34. Simon K: Diagnostyka i leczenie nadciśnienia wrotnego ze szczególnym uwzglȩdnieniem metod endoskopowych. Przegl Epidemiol 2006, 60, 715-724.
35. Vlachogiannakos J, Tang AKW, Patch D, Burroughs AK: Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001, 49, 303-308.
36. Nasr AA, Gad El- Hak N, Settein ME, Khafagy MA, Tadros MTY: Effects of angiotensin converting enzyme inhibitors and sclerotherapy on portal hemodynamics in patients with portal hypertension. Hepatogastroenterology 2000, 47, 795-806.
37. Ramalho FS, Ramalho LNZ, Castro-e-Silva O, Zucoloto S, Correa FMA: Effect of angiotensin converting enzyme inhibitors on liver regeneration in rats. Hepatogastroenterology 2002, 49, 1347-1351.
38. Jeffery TK, Wanstall JC: Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001, 92, 1-20.
39. Morrell NW, Morris KG, Stenmark KR: Role of angiotensin converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995, 269, H1186-H1194.
40. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T: Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004, 43, 142-152.